Notice of Public Hearing
Pursuant to subsection E of § 54.1-3443, the Board of Pharmacy is giving notice of a public hearing to consider placement of a chemical substance in Schedule IV of the Drug Control Act. The public hearing will be conducted at 9:05 a.m. on December 6, 2023. Instructions will be included in the agenda for the board meeting, also on December 6th. Public comment may also be submitted electronically or in writing prior to December 5th to Caroline Juran, Executive Director of the Board of Pharmacy to firstname.lastname@example.org.
Pursuant to article § 54.1-3443(E), the following drug will be removed from Schedule IV to conform with federal scheduling actions taken from February 4, 2023 to November 13, 2023:
- ZURZUVAE (zuranolone) 1-[2-[(3 R, 5 R, 8 R, 9 R, 10 S, 13 S, 14 S, 17 S)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1 H -cyclopenta[ a ]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile).